31575-15-2

Usage

Uses

Used in Pharmaceutical Applications:
Esculetin is used as a therapeutic agent for its potential in treating conditions such as osteoporosis and neurodegenerative diseases due to its ability to inhibit blood clotting and its neuroprotective properties.
Used in Antimicrobial and Antifungal Applications:
Esculetin is utilized as an antimicrobial and antifungal agent, given its ability to combat various microorganisms, making it a candidate for the development of new pharmaceuticals in the field of infectious diseases.
Used in Antioxidant and Anti-Inflammatory Applications:
Esculetin is employed as an antioxidant and anti-inflammatory agent, leveraging its properties to protect against oxidative stress and reduce inflammation, which are important in the treatment and management of various diseases and conditions.
Used in Research and Development:
Esculetin is used in research and development for its potential applications in medicinal chemistry, where its properties are further explored for the development of new drugs and therapies.
Used in Industrial Applications:
Esculetin may also find use in industrial applications, such as in the development of nutraceuticals and cosmeceuticals, where its antioxidant and anti-inflammatory properties can be harnessed for health and beauty products.

Upstream product

• 608-25-3 2-methylbenzene-1,3-diol 
• 607-97-6 ethyl 2-ethyl-3-oxobutanoate 

Downstream Products

• 670243-57-9 C₂₁H₂₀O₄ 
• 858741-53-4 6-ethyl-2,3,5,9-tetramethyl-7H-furo[3,2-g]chromen-7-one 
• 28814-59-7 6-ethyl-3,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one 

Relevant academic research and scientific papers

Design, synthesis, and antifungal evaluation of novel coumarin-pyrrole hybrids

A series of coumarin derivatives bearing a pyrrole scaffold were designed, prepared, and assessed for their in vitro antifungal activities against six phytopathogenic fungi. The antifungal activity screening results suggest that some synthesized hybrids exhibited potential fungicidal activities against the tested fungi. In particular, compounds 6j, 6k, 6o, 6p, and 6r displayed significant antifungal effects against Rhizoctorzia solani, and possessed EC50 values of 3.94, 7.75, 6.38, 6.25, and 7.67 μg/ mL, respectively. The above activities are more potent than the commercialized fungicide Boscalid (11.52 μg/mL) and Osthole (9.79 μg/mL). These results provide a significant reference for further rational design of coumarin-based fungicides.

Design, synthesis and antifungal activity of psoralen derivatives

A series of linear furanocoumarins with different substituents have been designed and synthesized. Their structures were confirmed by 1H-NMR spectroscopy, high resolution mass spectra (EI-MS), IR, and X-ray single-crystal diffraction. All of the target compounds were evaluated in vitro for their antifungal activity against Rhizoctorzia solani, Botrytis cinerea, Alternaria solani, Gibberella zeae, Cucumber anthrax, and Alternaria leaf spot at 100 μg/mL, and some of the designed compounds exhibited potential antifungal activities. Compound 3a (67.9%) exhibited higher activity than the control Osthole (66.1%) against Botrytis cinerea. Furthermore, compound 4b (62.4%) represented equivalent antifungal activity as Osthole (69.5%) against Rhizoctonia solani. The structure-activity relationship (SAR) study demonstrates that linear furanocoumarin moiety has an important effect on the antifungal activity, promoting the idea of the coumarin ring as a framework that might be exploited in the future.

Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives

A number of 7-hydroxycoumarins have been synthesised by Pechmann cyclisation using differently substituted resorcinols employing perchloric acid as the condensing agent. All the compounds have been characterised by analytical and spectroscopic methods. The anti-inflammatory properties were tested with LPS-induced inflammation in J774 macrophages. Expression of iNOS and COX-2 was determined by Western blot, NO by nitrite assay and IL-6 by ELISA analyses. Fifteen of the tested 7-hydroxycoumarins also inhibited IL-6 production but none of them had any major inhibitory effect on COX-2 expression.